What changed
$QGEN — WATCHLIST 📊
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide.
🎯 Q2 2026 | EPS $0.54 vs $0.54 ➖
💡 The market correctly anticipated QGEN's in-line earnings, and consensus growth estimates remain modest. No material mispricing is evident—neither overly pessimistic nor overly optimistic—leaving no alpha opportunity from an expectations reset.
📉 Reward/risk: 1.7:1
🏢 Business Quality: 7/10
📊 Valuation: fair — based on P/E ~18x annualized EPS of $2.16, which is in line with diagnostic peers' 15-20x range and QGEN's own 5-year average.
🔮 Catalyst: Q1 2026 Earnings Release (March 31,2026)
💰 Entry: $38.73, stop $35.0, target $44.0
📊 Our read: WATCHLIST. Full analysis →
https://stockduty.xyz/s/QGEN0625